A Randomized, Double-blinded, Active-controlled, Parallel, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of CMG-OLT-120 in Obese Patients

CMG Pharmaceutical0 个研究点目标入组 180 人开始时间: 待定最近更新: 2019年12月16日

适应症

试验速览

阶段: 未知
状态: 招募中
发起方
入组人数: 180

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional Study

入排标准

年龄范围: 19(Year) 至 69(Year)（—）
性别: All

入选标准

•1. Adults over 18 and under 70
•2. Obese patients with a BMI of 30 kg/m2 or more or obese patients with 27 kg/m2 or more with other risk factors (e.g., hypertension, diabetes, dyslipidemia) at Screening
•3. Those who agree to participate in the diet program during the clinical trial
•4. Those who signed an informed consent form voluntarily agreeing to participate in this clinical trial by themselves or a legal representative

排除标准

•1. Persons who have difficulty in evaluating anthropometric measurement due to anatomical changes such as ablation of a part of the body by surgery
•2. Within 1 month prior to screening, those taking Appetite suppressant, Chinese medicine for weight control, Dietary supplement, Insulin, Oral hypoglycemic agent, Beta-blocker, Diuretic, Fish oil supplements, Statin, Oral retinoid, Oral steroid, Thyroid hormone, Cyproheptadine, Phenothiazine, Oral contraceptive, Fiber supplement such as Polyglycoplex, Cyclosporine, GLP-1 receptor agonist, etc.
•3. Patients who have had surgery to lose weight: gastroplasty, intestinal resection
•4. Persons unable to orally administer capsules or tablets due to disease or surgery
•5. Patients with chronic malabsorption syndromes (e.g., chronic gastritis, chronic indigestion, irritable bowel syndrome, etc.) or patients with cholestasis
•6. Those who are or need to administer antiretroviral drugs (e.g., atazanavir, ritonavir, tenofovir disoproxil fumarate, etc.)
•7. Persons receiving or need to receive stable amiodarone therapy
•8. Uncontrolled diabetic patients (HbA1c > 7.5 %)
•9. Uncontrolled hypertension patients (SBP = 160 mmHg or DBP = 100 mmHg)
•10. Persons whose AST or ALT at Screening is three times or more than the normal upper limit
•11. Persons whose Creatinine at Screening is two times or more than the normal upper limit
•12. Patients with a history of severe heart disease (NYHA Functional Class III or IV heart failure, myocardial infarction within 6 months, ventricular tachyarrhythmias or unstable angina requiring treatment, etc.)
•13. Those who quit smoking within 6 months prior to Screening
•14. Those who lose 4 kg or more within 3 months prior to Screening
•15. Patients with a history of malignant tumor within 5 years prior to Screening (Registration is possible if the malignant tumor does not recur for more than 5 years. Registration is possible for basal cell carcinoma or for intracutaneous squamous cell carcinoma that does not recur after ablation.)
•16. Persons with organic causes of obesity at Screening (e.g., hypothyroidism; TSH level 4.2 mIU/L or more)
•17. Those who have a history of alcoholism or drug misuse
•18. Pregnant or lactating women
•19. Women and men of childbearing age who do not agree to medically accepted contraception during the clinical trial
•20. Patients who are scheduled to participate in another clinical trial after enrollment in this study or who have participated in an interventional clinical trial (drug/medical device) within 30 days prior to enrollment in this study
•21. Others who are deemed difficult to conduct clinical trials because they cannot understand the purpose, method, etc. of this clinical trial when investigator judges

研究者

发起方

CMG Pharmaceutical

相似试验

进行中（未招募）

不适用

A study to evaluate the effect of LCZ696 on artery stiffness in subjects with high blood pressure.

EUCTR2012-005720-15-GBovartis Pharma Services AG110

进行中（未招募）

1 期

A study to evaluate the effect of LCZ696 on artery stiffness in subjects with high blood pressure.Hypertensive patients.MedDRA version: 17.1Level: SOCClassification code 10047065Term: Vascular disordersSystem Organ Class: 10047065 - Vascular disordersMedDRA version: 17.1Level: PTClassification code 10015488Term: Essential hypertensionSystem Organ Class: 10047065 - Vascular disorders

EUCTR2012-005720-15-DEovartis Pharma Services AG110

尚未招募

不适用

A comparative safety and efficacy evaluation of different formulations on Healthy Subjects with Spondylitis Difficulties.

CTRI/2021/12/038614Akay Natural Ingredients Pvt Ltd

尚未招募

不适用

A clinical study to assess the safety and efficacy of CLV 0025P in Subjects Having Metabolic disorders.

CTRI/2020/10/028577Akay Natural Ingredients Pvt Ltd

进行中（未招募）

1 期

A Randomized, Double-blind, Active-controlled, Parallel Group, Stratified, Multi-center, 12-Week Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™ 250/10mcg twice daily) in a Single Inhaler (SkyePharma HFA pMDI) with the Administration of Fluticasone (250mcg twice daily) Alone in SkyePharma HFA pMDI and Flovent® HFA pMDI in Adolescent and Adult Patients with Moderate to Severe Asthma.

EUCTR2007-005653-37-CZSkyePharma AG375